BIOTRONIK SE & Co.KG

282 articles about BIOTRONIK SE & Co.KG

• BIOTRONIK Enrolls First Patient Into BIO-CONDUCT, First IDE Trial to Study Use of Stylet-Driven Leads for Conduction System Pacing

  12/13/2022

  BIOTRONIK, a global leader in the treatment of cardiac and vascular disease is pleased to announce the first patient enrollment in BIO-CONDUCT, an FDA approved investigational device exemption (IDE) trial examining the use of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area, a location for which the Solia S lead is not currently approved.

• BIOTRONIK, Inc. Reaches Settlement with U.S. Department of Justice

  7/22/2022

  BIOTRONIK, Inc. announced today that it has entered into a civil settlement with the U.S. Department of Justice, the U.S. Attorney's Office for the Central District of California, and the U.S. Department of Health and Human Services, Office of Inspector General, to resolve historical claims of alleged overuse of paid consultants to train field personnel and limited instances of excessive customer meals and travel.

• Latest Study Shows New Algorithm Can Predict Heart Failure Hospitalizations

  8/18/2021

  BIOTRONIK announced the results from a new study published in EUROPACE this week confirming that heart failure decompensation can be predicted early when monitored using an algorithm that combines existing remote monitoring trends and baseline risk stratification.

• BIOTRONIK's Implantable Cardiac Monitor Receives Prestigious Industry Award

  7/28/2021

  In association with Heart Rhythm 2021, BIOTRONIK announced that the latest implantable cardiac monitor, BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range of innovation and customer value criteria.

• 

  Philadelphia, Pacific Northwest See Surge in Biopharma Jobs

  5/14/2021

  Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here’s a look.

• FDA Clears Fever-Detecting Vital Data Sensor in New Cardiac Monitor

  12/16/2020

  BIOTRONIK  today announced FDA clearance and availability of the Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new BIOMONITOR IIIm injectable cardiac monitor (ICM), as shown in a published case report 1 .

• New Alliance Maps the Way in Electrophysiology

  5/20/2020

  A New Strategic Alliance Between BIOTRONIK, A Leader In Cardiac Rhythm Management, and Acutus Medical, Electrophysiology Innovator, Expected to Offer More Efficient and Effective Diagnosis and Treatment for Arrhythmia Patients   [20-May-2020]   CARLSBAD, Calif. and BERLIN , May 20, 2020 /PRNewswire/ --  Acutus Medical and BIOTRONIK today announced a new alliance to p

• BIOTRONIK's Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years

  2/24/2020

  Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to Outperform Abbott's Xience

• BIOTRONIK, Inc. Appoints David Hayes, MD, as Chief Medical Officer

  1/27/2020

  BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer

• Prix Galien Selects BIOTRONIK's PK Papyrus Covered Coronary Stent as Award Finalist

  7/31/2019

  PK Papyrus Stent Delivers Emergency Treatment for Acute Coronary Artery Perforations

• BIOTRONIK Receives FDA Clearance on Next-Gen Injectable Cardiac Monitor: BIOMONITOR III

  7/8/2019

  BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatment.

• Late-Breaking Data at EuroPCR: BIOTRONIK's Orsiro Demonstrates Unique Benefits in Small Vessels

  5/21/2019

  A Subgroup Analysis of the BIO-RESORT RCT Three-Year Data Showed Significant Differences in Efficacy in Favor of Ultrathin Strut Orsiro   [21-May-2019]   PARIS and BUELACH, Switzerland , May 21, 2019 /PRNewswire/ -- Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion re

• Focusing on Women: BIOTRONIK Launches Study to Understand the Impact of ICDs in NICM Patients

  5/6/2019

  BIO-LIBRA Study Aims to Break the Tradition of Underrepresentation of Women in Heart Disease Studies

• US Physicians Now Treating Patients with BIOTRONIK's Ultraslim Acticor DX Devices

  4/29/2019

  New Hybrid ICDs Feature Increased Longevity, Smooth BIOshape and Simplified DF4 Header Configuration

• BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US

  4/10/2019

  Lifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations

• InfoBionic Signs BIOTRONIK as Exclusive U.S. Distributor for MoMe® Kardia

  8/28/2018

  InfoBionic today announced an exclusive, strategic agreement with medical device manufacturer BIOTRONIK for U.S. distribution of InfoBionic’s proprietary MoMe® Kardia system, effective immediately.

• CORRECTING and REPLACING InfoBionic has Entered into an Exclusive Distributorship with BIOTRONIK for MoMe® Kardia in the U.S.; Expects Significant Nationwide Growth

  8/28/2018

  NFOBIONIC HAS ENTERED INTO AN EXCLUSIVE DISTRIBUTORSHIP WITH BIOTRONIK FOR MOME® KARDIA IN THE U.S.; EXPECTS SIGNIFICANT NATIONWIDE GROWTH

• BIOTRONIK Advances Arrhythmia Detection and Diagnosis with MoMe Cardiac Monitor in the US

  8/27/2018

  Industry's Only Full Disclosure External Cardiac Monitor Provides Immediate Near Real-Time Data

• Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US

  4/19/2018

  Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology.

• BIOTRONIK Release: CASTLE-AF Results Published in the New England Journal of Medicine, Showing Mortality Reduction for Heart Failure Patients

  2/1/2018

  This reduction was observed when compared to patients treated with the pharmacological therapy recommended by current guidelines.